42 results about "Testis specific" patented technology

The identification of a novel mutation in the testis specific Y-like gene and association of the mutation with SIDDT syndrome are disclosed. Methods for diagnosing SIDDT syndrome are disclosed. Methods for identifying compounds for use in the diagnosis and treatment of disorders associated with mutation in the TSPYL gene are also disclosed. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits.

A method of generating neural stem cells or motor neurons is disclosed, the method comprising up-regulating a level of at least one exogenous miRNA and/or down-regulating at least one miRNA using an agent which hybridizes to the miRNA in mesenchymal stem cells (MSCs) or down-regulating Related to testis-specific, vespid and pathogenesis protein 1 (RTVP-1).

The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Cervical cancer cells and HPV⁺ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.

A method of testing sperm quality including obtaining a sample of sperm to be tested; detecting and measuring the testis-specific HspA2 chaperone protein (or, the chaperone protein homologues to HspA2) in human and animal sperm; and determining a sperm quality parameter based upon the chaperone protein, wherein an increased amount of the chaperone protein species indicates a higher sperm quality. The chaperone protein is detected and measured either by binding one or more antibodies specific to the sperm chaperone protein to the sperm and measuring the antibody content or measuring ATP bound to the sperm chaperone protein. In the case of the latter method, the chaperone protein may be detected and measured by measuring ATP bound to the sperm chaperone protein, and such measuring is by chaperone protein-bound and CK-B generated ATP measurement, or by bioluminescence of the chaperone protein bound-ATP.

The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

The present invention provides a preparation method of testicular specific protein 50 humanized single-chain antibody. Said invention utilizes phage antibody presentation technique and adopts the following steps: using human testicular specific protein 50 as target antigen, utilizing immunoaffinity screening process to screen the recombinant phage human antibody variable region gene library, separating and cloning TSP 50 specific single-chain antibody gene AI,AII and C8, then respectively inserting single-chain antibody gene AI, AII and C8 into prokaryotic expression vector PelB, transforming Rosetta microphyte, utilizing IPTG to induce and express exogenous protein, after the thallus is cracked, ulitizing Ni-NTA column affinity chromatography to obtain purified single-chain antibody, utilizing ELISA method to judge that it can be specifically combined with TSP 50 holoprotein and 50 peptide, and using gene engineering measure to massively express said hamonized single-chain antibody. Said invention also discloses application of the testicular specific protein 50 humanized single-chain antibody for diagnosing and curing the diseases of female mammary carcinoma, etc. related to TSP 50.

The invention provides novel STAMP2 nucleic acid molecules, polypeptides, antibodies, and modulatory compounds for use in methods of diagnosing, treating, and preventing diseases and conditions of the prostate and testis, such as cancer.

Disclosed herein is a method for enhancing sensitivity of cancer cells to compounds or radiation by inhibiting the expression of testis-specific protein, Y-encoded like 5 (TSPYL5). More specifically, because methylation of TSPYL5 protein expressed in lung cancer cell line was inhibited to increase the expression level of the gene, resistance to stress such as radiation or anticancer agents was increased. Because the sensitivity of cancer cells to stress such as radiation or anticancer agents was increased by inhibiting the expression of the TSPYL5 gene to promote the apoptosis of the cells, an anticancer supplement agent containing an inhibitor of the expression or activity of the TSPYL5 gene of the present invention inhibits the growth of cancer cells and enhances the sensitivity to various stresses to maximize the apoptosis. Thus, when used in combination with radiotherapy or chemotherapy, the anticancer supplement agent may be used very usefully for anticancer treatment.

Provided herein are modified insects having decreased expression of a testis-specific coding region compared to a control insect. In one embodiment, the modified insect includes the characteristic of reduced fertility, reduced fecundity, or a combination thereof, when compared to the control insect. Optionally and preferably, the competiveness of the modified insect is not significantly reduced compared to the control insect. Also included herein are methods for making a modified insect, and methods for using the modified insects, including making populations of modified insects and use of the modified insects in sterile insect technique for biological control.

The invention provides novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, antibodies, and modulatory compounds for use in methods of diagnosing, treating, and preventing diseases and conditions of the prostate and testis, such as cancer.

The present invention relates to a peptide suppressing the phosphorylation of threonine (T120), the 120th residue of TSPYL5 (testis-specific Y-like protein 5), which is specifically as follows. The present inventors constructed T120D, the mutant of the 120th residue threonine (T120) of TSPYL5, and T120A-TSPYL5 gene and then transfected cells with them in order to investigate the effect of phosphorylation on T120 residue. As a result, wild-type TSPYL5 and T120D moved into nucleus and stayed there. But in the case of T120A-TSPYL5, TSPYL5 did not move into nucleus and instead it was expressed only in cytoplasm. The protein could not bind to AKT, either. Instead, ubiquitination of TSPYL5 was increased but SUMOylation was inhibited. Also, the expressions of ALDH1-A1, -A3, CD44 gene and protein were reduced, and thereby the growth and metastasis of lung cancer cells were suppressed and sphere formation was reduced. Based on the observation above, the inventors constructed the peptide composed of the amino acid sequences represented by SEQ. ID. NO: 43 or NO: 44 that could inhibit phosphorylation of the 120th residue threonine of TSPYL5. The said peptide can be effectively used as a composition for the inhibition of cancer cell growth, metastasis, and cancer stem cell growth.

A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.

The invention belongs to the field of biotechnology and medicine, and discloses a new human epididymis specific expression sperm binding protein HEL-90 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-90 protein and provides a recombination expression carrier carrying the DNA sequence for encoding the protein. The protein is located in the middle rear and tail parts of a mature sperm. A RT-PCR result shows that the gene is mainly and specifically expressed in the epididymis and testis and is negative in the heart, liver, spleen, kidney and stomach. A band of about 24 KD is detected in the corpus epididymidis part with Western blot. The HEL-90 protein can be used as a target protein for researching and developing immunity contraceptive as well as clinical diagnosis and treatment for male sterility. A method for detecting a corresponding gene or protein based on development of the HEL-90 protein can be widely used for the research field of reproductive medicine.

This invention relates to hepatic cancer-testis specific anti-genetic protein and anti-genetic peptide. The anti-genetic protein has the amino acid sequence shown in SEQ ID No. 1 (from AA 108-AA 191). The anti-genetic protein and anti-genetic peptide can be used as E2F activity-blocking agent in PRB/E2F signal transduction, and have antagonistic effects on homologous analogue TEDP-1. The tumor antigen protein can decompose in cells to obtain peptide fragments, which can bind with the main histocompatibility complex (MHC)-I molecules, and be recognized by T cells. The anti-genetic protein and anti-genetic peptide can be applied in anti-tumor drugs.

The invention discloses a sorting method of macrophages in testis, and relates to the technical field of biological cells. The invention provides an application of CD74 as a protein marker in macrophage sorting. Through a large number of experimental screening, the inventor finally finds that compared with existing common macrophage protein markers including F4/80, CD206, CD86, CD68, CD14, CD163 and CD11b, the testis macrophage protein marker CD74 disclosed by the invention has wider expression in a testis macrophage group, and shows the strongest testis specificity; by adopting the sorting method for the macrophages in the testis, the testis macrophages can be accurately and efficiently separated.